Who makes VVN461 Ophthalmic Solution 0.5%?

VVN461 Ophthalmic Solution 0.5% is developed by VivaVision Biotech, Inc.

What development phase is VVN461 Ophthalmic Solution 0.5% in?

VVN461 Ophthalmic Solution 0.5% is in Phase 2.

Last reviewed 2026-04-19 · How we verify

VVN461 Ophthalmic Solution 0.5%

VivaVision Biotech, Inc · Phase 2 active Small molecule

At a glance

Generic name	VVN461 Ophthalmic Solution 0.5%
Sponsor	VivaVision Biotech, Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery (PHASE2)
Pharmacokinetics of VVN461 Ophthalmic Solution (PHASE1)
A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VVN461 Ophthalmic Solution 0.5% CI brief — competitive landscape report
VVN461 Ophthalmic Solution 0.5% updates RSS · CI watch RSS
VivaVision Biotech, Inc portfolio CI